To review associations between frailty, infection risk and vaccine antibody responses in kidney transplant recipients and discuss frailty assessment before transplantation.
Approach:
: A single-center retrospective study followed 90 kidney transplant recipients aged 50 and older for at least 12 months to assess urinary tract infections.
: A retrospective analysis examined severe infection across 185,742 hospitalizations involving adults with prior kidney transplants.
: A vaccine-response study assessed seroconversion after two BNT162b2 doses in 101 kidney transplant recipients aged 70 and older without prior SARS-CoV-2 infection.
Key Findings:
In the UTI study, 33 of 90 recipients (37%) developed at least one UTI. Frailty was associated with a higher UTI hazard (hazard ratio, 8.13; 95% CI, 1.89–34.91). Among recipients with frailty, 12 of 21 UTI episodes (57%) occurred within 30 days after transplantation.
Severe infection occurred in approximately 51% of hospitalizations in the highest Hospital Frailty Risk Score category versus 24% in the lowest. The highest-risk group had higher adjusted odds of severe infection (adjusted odds ratio, 3.18).
In the vaccine study, 33% seroconverted after two doses. Frailty was associated with lower odds of seroconversion (odds ratio, 0.14). These findings concerned antibody responses, not subsequent clinical infection rates.
A survey found that 40% of transplant infectious diseases specialists routinely assessed frailty.
Interpretation:
The findings associate frailty with increased infection risk and weaker vaccine antibody responses but do not establish that frailty causes infection or that interventions targeting frailty prevent it. Maricar Malinis, MD, recommended assessment at transplant listing and reassessment at admission, alongside addressing deficits in strength, mobility and nutrition.
Limitations:
The UTI study was small and conducted at one center; its wide confidence interval indicated uncertainty about the association’s magnitude.
The hospitalization analysis relied on diagnostic coding and lacked transplant dates and pretransplant frailty measurements.
Much of the available evidence comes from small, single-center retrospective studies using different assessment tools. No single frailty assessment approach is considered the gold standard.
Conclusion:
Frailty assessment may help identify vulnerable transplant candidates and measurable deficits. Whether it should guide antimicrobial prophylaxis, cytomegalovirus monitoring or other infection-prevention strategies remains uncertain. Further studies are needed to determine whether frailty-guided interventions improve infection outcomes.